Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
作者： Robert M. Guthrie
DOI: 10.1080/00325481.2015.1044756
关键词: Type 2 Diabetes Mellitus 、 Glycated hemoglobin 、 Endocrinology 、 SGLT2 Inhibitor 、 Dipeptidyl peptidase-4 、 Metformin 、 Combination therapy 、 Pharmacology 、 Tolerability 、 Internal medicine 、 Medicine 、 Dipeptidyl peptidase-4 inhibitor
摘要: Abstract Objective. To review the efficacy, safety, and tolerability of combination treatment regimens including a dipeptidyl peptidase-4 (DPP-4) inhibitor and/or sodium-glucose cotransporter 2 (SGLT2) for type diabetes mellitus (T2DM). Methods. Clinical trials therapies DPP-4 SGLT2 were identified through PubMed database search. be included, studies had to have primary end point change from baseline ≥24 weeks in glycated hemoglobin, include ≥1 other oral antidiabetic drug (OAD), randomized more than 200 patients. Results limited medications approved by US Food Drug Administration at time search (March 2015). Results. A total 1534 articles class 434 retrieved PubMed. Of these, 33 24 included review. In each study, addition ...
sci-hub.se 参考文章(92)
B Göke, B Gallwitz, J Eriksson, Å Hellqvist, I Gause‐Nilsson, D1680C00001 Investigators, None, Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial International Journal of Clinical Practice. ,vol. 64, pp. 1619- 1631 ,(2010) , 10.1111/J.1742-1241.2010.02510.X
S. M. Poucher, S. Cheetham, J. Francis, B. Zinker, M. Kirby, S. P. Vickers, Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β‐cell mass in a streptozotocin‐induced mouse model of type 2 diabetes Diabetes, Obesity and Metabolism. ,vol. 14, pp. 918- 926 ,(2012) , 10.1111/J.1463-1326.2012.01619.X
Xia Liu, Qian Xiao, Li Zhang, Qiao Yang, Xiaoyan Liu, Lingjie Xu, Wen Cheng, The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis. Pharmacoepidemiology and Drug Safety. ,vol. 23, pp. 687- 698 ,(2014) , 10.1002/PDS.3586
D. R. Owens, R. Swallow, K. A. Dugi, H. J. Woerle, Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study1 Diabetic Medicine. ,vol. 28, pp. 1352- 1361 ,(2011) , 10.1111/J.1464-5491.2011.03387.X
R. R. Henry, A. V. Murray, M. H. Marmolejo, D. Hennicken, A. Ptaszynska, J. F. List, Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. International Journal of Clinical Practice. ,vol. 66, pp. 446- 456 ,(2012) , 10.1111/J.1742-1241.2012.02911.X
Krzysztof Strojek, KH Yoon, V Hruba, M Elze, AM Langkilde, S Parikh, None, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial Diabetes, Obesity and Metabolism. ,vol. 13, pp. 928- 938 ,(2011) , 10.1111/J.1463-1326.2011.01434.X
Burkhard Göke, Baptist Gallwitz, Johan G. Eriksson, Åsa Hellqvist, Ingrid Gause-Nilsson, Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. International Journal of Clinical Practice. ,vol. 67, pp. 307- 316 ,(2013) , 10.1111/IJCP.12119
Victor Lawrence Roberts, John Stewart, Maher Issa, Barbara Lake, Robert Melis, Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study Clinical Therapeutics. ,vol. 27, pp. 1535- 1547 ,(2005) , 10.1016/J.CLINTHERA.2005.10.017
S. Del Prato, R. Camisasca, C. Wilson, P. Fleck, Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes, Obesity and Metabolism. ,vol. 16, pp. 1239- 1246 ,(2014) , 10.1111/DOM.12377
T. Forst, R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger, P. Stein, Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, Obesity and Metabolism. ,vol. 16, pp. 467- 477 ,(2014) , 10.1111/DOM.12273